文献速递肝胆胰外科围术期管理与 ERAS

择期机器人与腹腔镜肝切除中降低中心静脉压的PRESSURE试验

Reduction of Central Venous Pressure in Elective Robotic and Laparoscopic Liver Resection: The PRESSURE Trial-A Randomized Clinical Study.
PubMed 文献 · Ann Surg · 2025-04-08

PRESSURE随机双盲试验比较微创肝手术中是否将中心静脉压(CVP)降至≤5 mmHg,共120例随机、112例分析。结果显示两组术中总出血量无差异,不降CVP组血流动力学不稳定更少,提示不降CVP策略安全且不增加出血。

要点

  • 微创肝切除中不降CVP与降CVP的术中总出血量相当。
  • 不降CVP组术中血流动力学不稳定发生率更低。
  • 不降CVP策略可避免液体限制的潜在不良影响。

核心结论

  • 微创肝切除肝实质离断期间不降低CVP是安全的,不增加术中出血量。
  • 不降CVP策略可能预防液体限制导致的血流动力学不稳定等不良效应。

研究设计与样本

  • 随机对照双盲试验,2020年8月至2023年4月择期微创肝手术患者等比例随机分为不降CVP组与麻醉干预降CVP组。
  • 共120例随机,112例纳入分析,两组围术期其他管理一致,主要终点为术中总出血量。

主要发现

  • 术中总出血量两组等效:不降CVP组280 mL(120-560) vs 降CVP组360 mL(150-640),P=0.30。
  • 肝实质离断期间出血量无差异:不降CVP组220 mL(80-400) vs 降CVP组240 mL(110-560),P=0.39。
  • 术后90天死亡率:不降CVP组3例(5%) vs 降CVP组2例(4%),P=0.68。
  • 总并发症率:不降CVP组10例(18%) vs 降CVP组11例(20%),P=0.77。
  • 术中血流动力学不稳定:不降CVP组7例(12%) vs 降CVP组16例(30%),P=0.03。

关键数值与推荐

  • 降CVP组目标为CVP≤5 mmHg,离断期间不降CVP组CVP为9.3 mmHg±4.2,降CVP组为3.2 mmHg±2.2,P<0.001。

临床怎么用

  • 微创肝切除肝实质离断期间可不常规降低CVP至≤5 mmHg,以减少血流动力学不稳定风险。
  • 不降CVP策略不增加术中出血,可避免液体限制相关的不良影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare perioperative outcomes in patients undergoing minimally invasive liver surgery (MILR) with or without central venous pressure (CVP) reduction (≤5 mm Hg). BACKGROUND: Reduction of CVP during parenchymal transection is widely accepted in open hepatectomy to reduce intraoperative blood loss, as a major predictor of postoperative outcomes. However, the effect of CVP reduction on blood loss in MILR remains unclear. METHODS: This study is a randomized controlled, double-blinded trial. Patients undergoing elective MILR between August 2020 and April 2023 were equally randomized to either no CVP reduction (No CVP reduction group) or CVP reduction by anesthesiological interventions (CVP reduction group). The remaining perioperative care was kept identical between groups. The primary endpoint was total intraoperative blood loss. RESULTS: In total, 120 patients were randomized and 112 were analyzed. Baseline characteristics did not differ between groups. Total intraoperative blood loss in MILR was equivalent between groups [No CVP reduction: 280 mL (120-560) vs CVP reduction: 360 mL (150-640); P = 0.30], despite higher CVP values during resection in the No CVP reduction group (9.3 mm Hg ± 4.2 vs 3.2 mm Hg ± 2.2; P < 0.001). Similarly, there was no difference in blood loss during parenchymal transection between the No CVP reduction (220 mL; 80-400) and the CVP reduction group (240 mL; 110-560; P = 0.39). Postoperative 90-day mortality (No CVP reduction: n=3, 5% versus CVP reduction: n=2, 4%; P = 0.68) and total morbidity rates (No CVP reduction: n = 10, 18% vs CVP reduction: n = 11, 20%; P = 0.77) were comparable. Intraoperative hemodynamic instability was less frequent in the No CVP reduction group (n = 7, 12% vs CVP reduction group: n = 16, 30%; P = 0.03). CONCLUSIONS: MILR without CVP reduction during liver transection is safe and is not associated with increased intraoperative blood loss. Moreover, a no CVP reduction strategy might prevent potential adverse effects of fluid restriction in MILR, such as hemodynamic instability.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Téoule P, Dunker N, Debatin J, et al. Reduction of Central Venous Pressure in Elective Robotic and Laparoscopic Liver Resection: The PRESSURE Trial-A Randomized Clinical Study. Ann Surg. 2025. PMID: 40197483. doi:10.1097/SLA.0000000000006721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。